CLDX Quote, Financials, Valuation and Earnings

Atossa Therapeutics, Inc. has a net margin of -7753.43% compared to Celldex Therapeutics, Inc.'s net margin of --. Celldex Therapeutics, Inc.'s return on equity of -32.17% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.

Celldex Therapeutics, Inc. has a consensus price target of $53.14, signalling upside risk potential of 79.54%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $5.69 which suggests that it could grow by 648.85%. Given that Atossa Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc. has a beta of 1.133, which suggesting that the stock is 13.281% more volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 0.950, suggesting its less volatile than the S&P 500 by 4.956%.

Celldex Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celldex Therapeutics, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.

Celldex Therapeutics, Inc. quarterly revenues are --, which are smaller than Atossa Therapeutics, Inc. quarterly revenues of --. Celldex Therapeutics, Inc.'s net income of -$67M is lower than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Celldex Therapeutics, Inc.'s price-to-earnings ratio is -- while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celldex Therapeutics, Inc. is 755.79x versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiora Pharmaceuticals, Inc. has a net margin of -7753.43% compared to Celldex Therapeutics, Inc.'s net margin of 84.08%. Celldex Therapeutics, Inc.'s return on equity of -32.17% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.

Celldex Therapeutics, Inc. has a consensus price target of $53.14, signalling upside risk potential of 79.54%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 411.63%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc. has a beta of 1.133, which suggesting that the stock is 13.281% more volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.753, suggesting its less volatile than the S&P 500 by 175.254%.

Celldex Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celldex Therapeutics, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Celldex Therapeutics, Inc. quarterly revenues are --, which are smaller than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Celldex Therapeutics, Inc.'s net income of -$67M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Celldex Therapeutics, Inc.'s price-to-earnings ratio is -- while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celldex Therapeutics, Inc. is 755.79x versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -7753.43% compared to Celldex Therapeutics, Inc.'s net margin of -735.19%. Celldex Therapeutics, Inc.'s return on equity of -32.17% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Celldex Therapeutics, Inc. has a consensus price target of $53.14, signalling upside risk potential of 79.54%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 147.59%. Given that Intellia Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..

Celldex Therapeutics, Inc. has a beta of 1.133, which suggesting that the stock is 13.281% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Celldex Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celldex Therapeutics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Celldex Therapeutics, Inc. quarterly revenues are --, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Celldex Therapeutics, Inc.'s net income of -$67M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Celldex Therapeutics, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celldex Therapeutics, Inc. is 755.79x versus 16.51x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -7753.43% compared to Celldex Therapeutics, Inc.'s net margin of 7.29%. Celldex Therapeutics, Inc.'s return on equity of -32.17% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Celldex Therapeutics, Inc. has a consensus price target of $53.14, signalling upside risk potential of 79.54%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that Celldex Therapeutics, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Celldex Therapeutics, Inc. is more attractive than Phibro Animal Health Corp..

Celldex Therapeutics, Inc. has a beta of 1.133, which suggesting that the stock is 13.281% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Celldex Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. Celldex Therapeutics, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Celldex Therapeutics, Inc. quarterly revenues are --, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Celldex Therapeutics, Inc.'s net income of -$67M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Celldex Therapeutics, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celldex Therapeutics, Inc. is 755.79x versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.